WEREWOLF THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $1.70 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-06-30 was -$221.00K, a 121.71% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-03-31 was $1.92M.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-12-31 was -$3.94M, a 252.26% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-09-30 was -$1.21M, a 241.93% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was -$4.33M, a 242.32% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2022 was $3.05M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$221.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $1.70M S-4 · filed 2026-09-22 | -$2.24M derived: sum of 3 quarters · filed 2026-09-22 | -$3.45M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $1.92M 10-Q · filed 2026-05-07 | -$2.02M derived: sum of 2 quarters · filed 2026-09-22 | -$3.23M derived: sum of 3 quarters · filed 2026-09-22 | -$2.21M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | -$3.94M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$5.15M derived: sum of 2 quarters · filed 2026-09-22 | -$4.13M derived: sum of 3 quarters · filed 2026-09-22 | -$7.50M S-4 · filed 2026-09-22 |
| 2025-09-30 | -$1.21M derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | -$187.00K derived: sum of 2 quarters · filed 2026-09-22 | -$3.55M 10-Q · filed 2025-11-04 | -$962.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $1.02M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | -$2.35M S-4 · filed 2026-09-22 | $243.00K derived: sum of 3 quarters · filed 2026-09-22 | $1.09M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | -$3.37M 10-Q · filed 2026-05-07 | -$775.00K derived: sum of 2 quarters · filed 2026-09-22 | $74.00K derived: sum of 3 quarters · filed 2026-09-22 | $2.56M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $2.59M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $3.44M derived: sum of 2 quarters · filed 2026-09-22 | $5.92M derived: sum of 3 quarters · filed 2026-09-22 | $3.46M S-4 · filed 2026-09-22 |
| 2024-09-30 | $849.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.33M derived: sum of 2 quarters · filed 2025-11-04 | $864.00K 10-Q · filed 2025-11-04 | $1.82M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $15.00K 10-Q · filed 2025-08-14 | $968.00K derived: sum of 3 quarters · filed 2025-08-14 | -$1.30M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$2.47M 10-Q · filed 2025-05-08 | -$1.52M derived: sum of 2 quarters · filed 2025-05-08 | -$3.79M derived: sum of 3 quarters · filed 2025-05-08 | -$7.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$1.32M derived: sum of 2 quarters · filed 2025-03-11 | -$5.24M derived: sum of 3 quarters · filed 2025-03-11 | -$4.33M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$6.19M derived: sum of 2 quarters · filed 2024-11-07 | -$5.29M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.02M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $903.00K 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $3.05M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |